Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, biopsy, Diagnosis, fusion, MRI, MRi-guided, MRI/TRUS, prognosis, scan | 3 Comments »
The Prostate Cancer Foundation posted two useful and basic articles on its blog site this December that may be useful resources for men concerned about their risk for or newly diagnosed with prostate cancer or monitoring their PSA over time (for any one of all sorts of possible reasons). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer | Tagged: accuracy, advice, diagnosed, guidance, newly, PSA, test | 4 Comments »
Two questions that come up regularly are whether: (a) men who are said to have died of prostate cancer actually did, and (b) men with prostate cancer who are said to have died of something else actually died of their prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: accuracy, cancer-specific, cause, death, mortality | 4 Comments »
Some people aren’t going to be happy about the following data, but they come from one of the most sophisticated prostate cancer imaging centers in the world … and they make it very clear indeed that multiparametric MRI scanning (mpMRI) is less than perfect in identification of risk for prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, false, mpMRI, negative, result, scan | 2 Comments »
A newly published article in BJU International has (finally) proven something many prostate cancer educators and advocates have known for years: many patients have a very poor appreciation of the risks and benefits of their differing treatment options at the time they make decisions about first-line treatment for localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: accuracy, benefit, knowledge, patient, risk, Treatment, understanding | 5 Comments »
Another presentation at the ASCO annual meeting yesterday morning came from the PROMIS trial in the UK. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, biopsy, Diagnosis, mpMRI, triage | 5 Comments »
A new study that is in press on line in the Journal of Urology addresses, very reasonably, the question of whether using targeted biopsy methods based on multiparametric MRI (mpMRI) data is improving our ability to accurately assess patient’s Gleason grades and scores prior to decisions about treatment. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: accuracy, biopsy, Gleason, MRI, multiparamentric, targeted | 7 Comments »
According to data from a large, prospective, multi-institutional trial carried out here in the USA, the 4KScore test has shown a high degree of ability to accurately identify men with a Gleason score of 3 + 4 = 7 or higher which was subsequently confirmed on prostate biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: 4Kscore, accuracy, Diagnosis, kallikrein, risk, test | 4 Comments »
A paper by Wong et al. published in December carries the title, “Diagnostic prostate biopsy performed in a non-academic center increases the risk of re-classification at confirmatory biopsy for men considering active surveillance for prostate cancer.” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, active, biopsy, re-classification, rebiopsy, risk, surveillance | 1 Comment »
The prostate cancer antigen 3 or PCA3 test was initially approved as an aid to the assessment of risk of prostate cancer in men with an elevated PSA level who had already been given at least one prior, negative biopsy. … READ MORE ..
Filed under: Diagnosis, Risk | Tagged: accuracy, Diagnosis, PCA3, risk, sensitivity | Leave a comment »
A cross-specialty group of prostate cancer experts has reviewed data from > 13,000 patients on the accuracy of nomograms in predicting biochemical recurrence and actual prostate cancer-specific mortality after three different types of treatment. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: accuracy, nomogram, outcome, recurrence, risk, survival | 6 Comments »
The “New” Prostate Cancer InfoLink wants to be clear for our readers that we are significantly less enthusiastic than others about some of the information being offered to patients, clinicians, and payers through the web site of an organization known as the Prostate Cancer Treatment Research Foundation (PCTRF). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: accuracy, outcomes, prognosis, projections, relevance | 11 Comments »
The role of personalized genetic and genomic testing and the value of such testing to test to accurately and reliably predict things like the appropriateness of active surveillance as a management strategy or the risk for recurrence after first-line surgery is now evolving at almost bewildering speed. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, test, type, value | 1 Comment »
Two newly published papers in the November issue of the Journal of Urology address prospective studies of the use of differing forms of MRI-guided biopsy in the diagnosis of prostate cancer. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: accuracy, biopsy, MRi-guided, MRI/TRUS fusion, TRUS-guided | 5 Comments »
There is a fascinating comment by Kattan scheduled for publication in a forthcoming issue of the new journal Urology Practice. It makes a truly critical point about whether any of the new biomarkers are actually adding significantly to what we know about how to assess risk for prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: accuracy, biomarket, endpoint, PSA, risk, test | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 